Agile Therapeutics Inc., of Princeton, N.J., said it priced its initial public offering of about 9.2 million shares at $6 apiece, for gross proceeds of $55.2 million, most of which will be used to fund an additional phase III trial for contraceptive candidate Twirla, a once-weekly patch designed to deliver hormones ethinyl estradiol and levonorgestrel. The company granted underwriters a 30-day option to purchase up to an aggregate of 1.4 million shares at the offering price to cover overallotments. RBC Capital Markets LLC and William Blair & Co. LLC acted as joint book-running managers, while Cantor Fitzgerald & Co. and Janney Montgomery Scott LLC are acting as co-managers. Agile's shares (NASDAQ:AGRX) closed Friday at $5.54, down 46 cents.